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INTRODUCTION
Since its founding in 1987, the Edison BioTechnology
Center has become the premier advocate for Ohio's
biomed/biotech industiy. As part of the Ohio Department
of Development's Thomas Edison Program, the Center
works closely with the state's leading universities and
medical institutions, businesses, foundations, and civic
and state organizations. Programs and services of EBTC
facilitate the growth of the industry, build a supportive
infrastructure, and help to create a national identity for
Ohio. One of EBTC's key functions is to track the growth
of Ohio's biomed/biotech industry. Presented here are
findings from EBTC's most recent state survey as well as
data from a number of national surveys. The challenges
facing Ohio as it takes its place as a key player in this
emerging industry are described.
DISCUSSION
EBTC Mission
EBTC has been monitoring, promoting, and
contributing to the growth of Ohio's biomedical and
biotechnology research and industry base for five
years. The center has not actively engaged in
biotechnology development involving agriculture, the
environment, and animals (other than human) to date.
Therefore, the comments offered in this paper are restricted
primarily to EBTC's present constituency: the
research and industry base in Ohio which focuses on the
use of biological processes to create products for
human health care and for the more well-established
biomedical devices industry which is based on Ohio's
strong manufacturing and materials base. EBTC
directs its programs to both the biomedical and the
biotechnology areas. It counts as members Ohio's major
research institutions (Case Western Reserve University,
Children's Hospital Research Foundation-Cincinnati,
The Cleveland Clinic Foundation, The Metro Health
System, The Ohio State University, Ohio University, the
University of Cincinnati, and University Hospitals of
Cleveland) as well as corporate members from all areas of
the state (Fig. 1).
EBTC fills a unique niche between Ohio's academic
and research institutions engaged in biomedical research
and a growing industry base; it supports this industry
through five programs:
1. Centers of Excellence—EBTC pursues multi-
institutional, multi-disciplinary consortia which
can assemble a critical mass of resources in
specific technology focus areas and increase
the probability of substantial technological
advances.
FIGURE 1. EBTC membership (8 Institutions, 60 Companies).
2. Technology Funding Programs—EBTC directs its
funding to projects which have near-term
commercial potential and can attract follow-on
financing for commercialization; its programs
strongly encourage alliances between Ohio
companies and research institutions in technology
development. Institutional research agenda are
not generally market-driven and may not always
match Ohio industry needs. The strategic plan of
EBTC defines a key role in assisting researchers
and companies to cooperatively address
recognized market needs.
3. Business Assistance—EBTC focuses on providing
services to emerging biomedical and
biotechnology companies in 'ways which will
nurture the growth of the industry base in Ohio.
One-on-one counselling, focus groups and key
introductions to clinical partners, potential
investors, etc., enable the entrepreneur to access
the extensive network of resources which EBTC
has assembled in five years of operation.
4. Education and Outreach Programs, Publications—
The programs provided by EBTC serve a variety
of education and networking objectives, and
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draw more than 1,000 participants annually.
Seminars feature topics of immediate interest and
utility to emerging companies (e.g., FDA regulatory
issues, commercialization strategies, and so forth);
topic selection is based on member surveys and
input from the industry. The Edison BioTechnology
Center offers special programs to meet the needs
of its institutional members. Currently in
development is a graduate-level training program
describing the FDA approval process, scheduled
to be offered at The Ohio State University later this
year. The center is also involved in the creation of
a bioscience education program for high school
biology teachers which has drawn industrial, public,
and foundation support. Publications provided by
EBCT enhance the flow of information to its
government, academic, corporate, and community
constituencies.
Industry Advocacy—A national identity for the
Ohio biomed/biotech industry is being built by
EBTC. Special surveys, the annual Directory of
Ohio Biomedical & Biotechnology Companies,
and EBTC's participation in national studies,
associations, etc., promote Ohio's expanding
role in an industry which is becoming increasingly
important to the national economy. The center is
in a unique position from which to observe the
industry and assess Ohio's participation. To
monitor industry development, EBTC draws upon
national surveys as well as its own studies.
National Level Outlook
The accounting firm of Ernst & Young annually studies
the national biotechnology industry, surveying companies
that use biological processes to develop products for
human health, animal health, agricultural productivity,
food safety and nutrition, energy enhancement, and
environmental conservation. The firm has just released its
1993 report (Burrill and Lee 1993), and key observations
indicate that the biotech industry is maturing and moving
towards the wide-spread launch of products that have
been in development for several years.
• Total revenues ($8.1 billion) are up 28% from the
last reporting period.
• Of survey respondents, 89% expect to launch
their first product by 1996.
• Ernst & Young predicts industry-wide profitability
by the mid-1990s, as a number of products clear
the FDA.
• Ohio now ranks 12th in the nation in number
of biotech companies, a 20% increase from
1991 (Fig. 2).
The next ten years are projected to be growth years for
the biomed/biotech industries. Investment in research
and development for human health care is increasing and,
FIGURE 2. Location of biotech companies in the United States as reported by Ernst & Young (1993).
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as more products obtain FDA approval and reach the
marketplace, industry-wide profitability is anticipated.
This optimistic outlook points to a promising future for
Ohio as it takes its place in the industry.
Outlook for Ohio's Industry
Competition among states for a key position in the
biomed/biotech industry is intensifying. Many states,
notably California, North Carolina, Maryland, New York,
Massachusetts, and Pennsylvania, have achieved national
prominence with well-established programs to support
the industry. In 1992, more than 80 biotechnology centers
were located across the United States, each with various
research, technology development, education, and business
support programs. Most are affiliated with major academic
research institutions and many are part of larger research
park and business incubation programs. All receive state
support through universities or regional development
programs. Advantages for Ohio in this competition are
significant and, if further developed, can make the state a
major player.
The biomed/biotech research and industry base in
Ohio is notable and should be a continued source of
economic growth for the state. Human health care will
remain a primary focus of investment for research and
development. A direct relationship between the level of
research funding provided by the National Institutes of
Health (NIH) and the number of biomed/biotech start-ups
has been demonstrated by EBTC. In 1990, Ohio ranked
tenth in the receipt of research dollars from NIH (Fig. 3);
continued NIH funding at present or greater levels should
have a positive effect on industry in the state.
This optimistic outlook is confirmed by EBTC's own
survey (Edison BioTechnology Center 1992) of the
biomed/biotech industry in Ohio, released in July 1992.
A key finding is that small to medium size companies
(annual sales less that $200 million) have experienced
significant growth over the last five years, with average
annual increases of 14.2% in employees and 17.8% in
sales (Fig. 4).
Furthermore, the rate of new company formation,
historically five starts per year, has been accelerating since
1985. Based on survey findings, EBTC predicts the formation
of at least 14 new companies by 1994; Ohio's small to
medium size biomed/biotech companies (in actual number
of companies, the largest segment of the industry) could
have aggregate sales as high as $650 million and an
employment level as high as 7,000 by that time.
Challenges to Ohio's Industry
Ohio faces several challenges in developing its biomed/
biotech industry.
1. Retaining the Benefits of New Technologies in
Ohio—In developing Ohio's technology base, it
is important to allow for alternative com-
Number of Companies









OHIO JOURNAL OF SCIENCE BAUNACI1 ET AL.
mercialization strategies. Wherever appropriate,
the teehnology itself should remain within the
state, either by transferring it to an Ohio company
or by forming a new Ohio-based company to
develop and market it. However, it must be
recognized that biotechnology is developed within
the context of a global market and depends to a
large extent on strategic alliances which can
underwrite the large research and development
efforts typical of many biotech products. In some
cases, it is more advantageous to the state to
recognize a particular technology as a product,
and market it to maximize the revenue return to
the state. Exploiting the full potential of
technological strength in Ohio thus challenges
the traditional cultures of both institutional
technology transfer offices, which have a bias
towards out-licensing, and state funding
departments, which define successful technology
transfer in terms of job creation or retention.
2. Ensuring Adequate Financing Mechanisms—
Research can be funded in the early stages
through a combination of foundation grants and
federal and state programs, but the entrepreneur
faces a funding gap when forming his/her
company to commercialize a product. He/she
may no longer qualify for continued support
from these early stage sources, most of which
direct funds through institutions rather than into
businesses, and the product is not yet sufficiently
developed to attract venture capital or bank
investment. In many cases, at this stage, the
entrepreneur must devote time and energy to
seeking private investors, at great cost to the
management of the business. The cost to the
economy is high when these growth-oriented
businesses fail. Projects with good commercial
potential may die before they can attract traditional
investment funds. At the very least, the
commercialization process will be slowed and
product introduction delayed.
Absence of seed funding is not the only financial
challenge. EBTC's survey found that over the
past five years, Ohio biomed/biotech companies
attracted only 10% of the venture capital
investments made in Ohio and accounted for
only 1% of all venture capital invested in biomed/
biotech ventures in the U.S
Growth in the biomed/biotech industry in general
will be tempered by the U.S. health care policy
decisions and FDA and other regulatory postures,
but the availability of capital, both seed funding
and venture capital investment, will be critical to
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the future of Ohio's industry.
3. Ensuring a Pool of Technically-trained Labor—A
scientifically literate pool of employees is
important for expansion or retention of emerging
biomed/biotech businesses in Ohio. The life
sciences have seen an explosion of knowledge
and the translation of that new knowledge into
technology in the past two decades. Unfortunately,
many primary and secondary school teachers
have not had the opportunity to become familiar
with advances in the life sciences and are
unprepared to incorporate this new and exciting
knowledge into the curriculum. Studies have
shown that students make career choices as early
as the seventh grade; it is imperative that efforts
be directed toward both teachers and students to
enhance the effectiveness of science education
and to encourage students in the pursuit of
careers in the life sciences.
Entrepreneurial Issues
In its national survey (Burrill and Lee 1992), Ernst &
Young identified four key factors in developing the
biotechnology industry:
1. Proximity to world-class research institutions.
2. Access to venture capital and other forms of
financing.
3. A climate which supports and nurtures the
entrepreneurial culture.
4. High quality of life/low cost of living factors.
Ohio has the basis for providing all four of these
elements, but further development is needed in each area.
Institutional researchers must be encouraged to see the
commercial potential of their work and to explore
that potential; institutional barriers which discourage
researchers from commercializing their work must be
eliminated.
Ohio is home to several large venture capital groups;
these firms must be encouraged to invest in Ohio-based
ventures and to assist in bringing venture capital to bear
from other regions of the country. In addition, innovative
ways of providing seed capital funding to assist early-stage
companies must be explored.
Ohio's incubator program provides a nurturing
environment for emerging businesses but on a small scale.
Supporting the entrepreneur/promoter who can envision
the commercial possibilities of an idea and, more
importantly, provide the push to translate that idea into a
marketable product, is a vital part of business development.
Finding new ways of providing that support will be critical
to the future of Ohio's industry.
Finally, quality of life factors can be related to the need
to develop locally, and to attract and retain the talented
labor pool which will be needed as the Ohio's biomed/
biotech industry matures.
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